cIAP2 Antibody (YA5260)

cIAP-2 (cellular inhibitor of apoptosis protein 2, encoded by BIRC3) is a member of the inhibitor of apoptosis protein (IAP) family that functions as a signaling regulator linking cell survival, inflammatory responses, and programmed cell death pathways^[1][2]. Mechanistically, cIAP-2 acts as an E3 ubiquitin ligase within TNF receptor and pattern-recognition receptor signaling complexes, where it contributes to ubiquitination-dependent activation of NF-κB signaling and downstream transcriptional programs that support cellular adaptation to stress and immune stimulation^[3][4]. Through cooperation with TRAF family proteins, cIAP-2 participates in the regulation of receptor-mediated signaling networks that control apoptosis, innate immunity, and inflammatory responses^[3][5]. In disease settings, altered BIRC3 expression or mutation has been associated with hematologic malignancies and other cancers, highlighting the importance of cIAP-2 in tumor cell survival and therapy response^[6][7]. Compared with the closely related isoform cIAP-1 (BIRC2), cIAP-2 displays distinct expression kinetics and regulatory patterns; cIAP-2 is strongly inducible by inflammatory cytokines through NF-κB-dependent mechanisms, whereas cIAP-1 is more constitutively expressed and is thought to support rapid signaling events^[4]. This distinction suggests that cIAP-2 may contribute preferentially to sustained or later-phase signaling responses following inflammatory stimulation^[4]. For experimental applications, cIAP-2 is widely investigated as a target of SMAC mimetics and other IAP-directed compounds that promote cIAP degradation or disrupt cIAP-associated signaling complexes, providing useful tools for studying NF-κB regulation, apoptosis sensitivity, and anticancer therapeutic mechanisms^[2][8].